There are no globally agreed upon treatment guidelines for patients with chronic hepatitis B virus (HBV) with multidrug resistance (MDR). We conducted a multicenter, prospective, real-world cohort study of effects of tenofovir disoproxyl fumarate (TDF) monotherapy and TDF-based combination therapy, as rescue therapy, in patients with multidrug-resistant chronic HBV infections.
H epatitis B virus (HBV) infection is one of the main
causes of chronic liver disease worldwide. 1 A high level of HBV DNA, which is indicative of active viral replication, has been identified as an independent risk factor for cirrhosis and hepatocellular carcinoma (HCC). [2] [3] [4] Thus, the therapeutic goal of antiviral therapy has been to sustain viral suppression in terms of an undetectable HBV DNA level. 5 Long-term use of oral antiviral agents is required to maintain the treatment response. However, the efficacy of antivirals has been reduced by the emergence of drug-resistant HBV mutants.
The clinical benefit of lamivudine (LAM) may be substantially offset by the high rate of resistance of up to 80% caused by the rtM204V/I and rtL180M mutations. 6, 7 Although adefovir (ADV) monotherapy or LAM plus ADV combination therapy can be applied as a rescue therapy, ADV monotherapy for LAM-resistant chronic hepatitis B (CHB) reportedly results in a modest cumulative rate of virologic response (VR) (48.8%) at 5 years. 8 Therefore, potent antiviral drugs, such as tenofovir disoproxil fumarate (TDF) or entecavir (ETV), are recommended. TDF, which has a high genetic barrier, shows both less-frequent resistance and an excellent VR. 9 Due to a lack of evidence, the current guidelines recommend different primary options, particularly for patients with multidrug resistance (MDR). The European Association for the Study of the Liver guidelines recommend TDF monotherapy or TDF plus ETV as the primary option. 10 By contrast, the American Association for the Study of Liver Diseases guidelines recommend TDF monotherapy as the primary option and TDF plus ETV as a secondary option. 11 For many years, only the sequential switch to ADV rescue therapy had been reimbursed when LAM resistance occurred in Korea, resulting in the frequent occurrence of MDR. Likewise, in Asia, where cost is an issue, there are many patients with MDR.
Few randomized clinical trials (RCTs) have investigated the outcomes of TDF monotherapy and TDF plus nucleos(t)ide analog combination therapy; those reported to date have involved a small number of patients who failed previous antiviral treatment. 12 In addition, these RCTs included patients who were selected by the criteria of the RCTs, and they therefore cannot reflect the various situations that may arise in a real-world setting. Thus, real-world studies are necessary because the results of RCTs alone are not likely to be useful in patients with comorbidities, and additional follow-up is required for problems that occur after the trials are terminated.
Thus, we conducted a large-scale real-world cohort study of the clinical efficacy and safety of TDF monotherapy and TDF-based combination therapy as a rescue therapy for patients with MDR.
Patients and Methods

Study Subjects
From May 2012 to November 2015, CHB patients who experienced antiviral resistance were recruited from the 8 tertiary hospitals in South Korea. The inclusion criteria were as follows: (1) !20 years of age, (2) confirmed CHB (defined as a positive serum hepatitis B surface antigen [HBsAg] test for at least 6 months), (3) confirmed genotypic resistance to antiviral treatment (MDR was defined as having at least 2 genotypic resistance), and (4) rescue therapy using TDF monotherapy or TDF-based combination therapy. The exclusion criteria were patients with other causes of liver disease (alcohol, autoimmune hepatitis, or Wilson's disease), decompensated liver disease or HCC at baseline, and those co-infected with hepatitis C virus.
This was a multicenter cohort study (NCT02019966). The study was performed in accordance with the ethical guidelines of the 1975 Declaration of Helsinki. This study was approved by the institutional review board of each institution. Written informed consent was obtained from patients or responsible family members.
Study Design
Patients with CHB were treated with TDF monotherapy (300 mg once daily) (TDF-Mono group) or TDF-based combination therapy (TDF 300 mg once daily plus LAM 100 mg, telbivudine 600 mg or ETV 1.0 mg once daily) (TDF-Combi group) at the discretion of their provider. Patients were followed up at regular intervals (3-6 months) after commencement of the rescue therapy. HBV DNA levels were determined by polymerase chain reaction (PCR) assays (Amplicor HBV Monitor Test, 20 IU/mL detection limit; Roche Diagnostics, Basel, Switzerland). Restriction fragment mass polymorphism assays were performed to identify the mutations associated with resistance to LAM (rtL180M or rtM204V/I/S), ADV (rtA181V/T or rtB236T) or ETV (rtI169T, rt184A/C/F/G/I/L/S, rtS202G, or rtM250L/V) at the time of rescue therapy and as necessary. 13 The upper limit of the normal alanine aminotransferase (ALT) range was defined as 33 IU/L for men and 25 IU/L for women. 14 Cirrhosis was defined as follows: 1) platelet count <100,000/mL and ultrasonographic findings suggestive of cirrhosis, including a blunted, nodular liver edge with splenomegaly (>12 cm); (2) ascites,
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Study Endpoints
The primary endpoint was the cumulative proportion of patients who achieved a VR, defined as a serum HBV DNA level of <20 IU/mL by real-time PCR, in patients with MDR during the follow-up. The secondary endpoints were the proportion of patients with ALT normalization, hepatitis B e antigen (HBeAg) loss or seroconversion (HBeAg-positive patients only), HBsAg loss or seroconversion, and change in HBV DNA level from baseline. Viral breakthrough (VBT) was defined as an increased HBV DNA level (>2000 IU/mL or !1 log 10 IU/mL from baseline) after nadir.
Statistical Analysis
The data are expressed as the mean AE SD, median (range), or number and percentage, as appropriate. Variables were examined by Student's t test (or Mann-Whitney U test, if appropriate) and the chi-square test (or Fisher's exact test, if appropriate). Cumulative rates were calculated using the Kaplan-Meier method and were compared by the log-rank test. The Logistic regression analysis was used for univariate and multivariate analyses. A 2-sided P value <.05 was considered to indicate statistical significance. Assuming success rates of 90% for both groups 16 and a 1-sided 10% noninferiority margin, and taking into account a dropout rate of up to 15%, the sample size needed to achieve 80% power was 300 patients in total based on a test for noninferiority of proportions. Considering the real-world cohort study, we tried to enroll more than 150 patients in each group. All statistical analyses were performed using the SPSS version 20.0 (IBM Corp, Armonk, NY).
Results
Baseline Characteristics
In total, 1,083 CHB patients who experienced any antiviral resistance were initially screened. Among 1,020 patients with antiviral resistance, 423 (41.5%) with MDR were included in the final analysis ( Figure 1 ). Overall, 174 (41.1%) patients received TDF monotherapy (TDF-Mono group) and 249 (58.9%) received TDF-based combination therapy (TDF-Combi group). The baseline characteristics of the study population are summarized in Table 1 . The mean age was 51.7 years, and men were predominant (n ¼ 309, 73.0%). HBeAg positivity was identified in 336 (79.4%) patients, and the mean serum HBV DNA level at the time of rescue therapy was 3.8 log 10 IU/mL. Of all patients, 93 (22.0%) showed cirrhosis at baseline. The TDF-Mono and TDF Combi groups showed similar baseline characteristics, with the exception of the proportion of cases with cirrhosis (28.7% vs 17.3%; P ¼ .005) and the composition of HBV-resistance mutations (P < .001). Patients with HBV resistance mutations to LAMþADV (47.8% vs 32.8%; P ¼ .003) and LAMþETVþADV (9.6% vs 2.3%; P ¼ .002) were more likely to receive the TDF-based combination regimen. By contrast, patients who had HBV resistance mutations to LAMþETV (64.9% vs 42.6%; P < .001) were more likely to receive TDF alone.
Virologic Response
During the follow-up period (median 180 [interquartile range, 120-228] weeks; total 16,615 personyears), the cumulative incidence rates of VR in the MDR group were 70.0% at 48 weeks, 85.5% at 96 weeks, 91.9% at 144 weeks, 94.8% at 192 weeks, and 96.4% at 240 weeks (Figure 2A ). In the TDF-Mono group, the cumulative rates of VR were 71.7% at 48 weeks, 85.1% at 96 weeks, 92.1% at 144 weeks, 93.4% at 192 weeks, and 97.7% at 240 weeks. In the TDF-Combi group, the cumulative rates of VR were 68.9% at 48 weeks, 84.2% at 96 weeks, 92.7% at 144 weeks, 95.7% at 192 weeks, and 97.2% at 240 weeks ( Figure 2B ). The cumulative rates of VR were not different between the TDF-Mono and TDF-Combi groups (P ¼ .966). Using a VR threshold of <60 IU/ mL, there were also no significant differences in the incidence rates of VR between the TDF-Mono and TDF-Combi groups ( Table 2) .
We also compared treatment response according to age group (!60 years of age vs <60 years of age), the presence of cirrhosis, chronic kidney disease (a decreased glomerular filtration rate of <60 mL/min/ 1.73 m 2 ) and drug-resistant mutations ( Supplementary  Figure 1 ). There were no significant differences in treatment response based on age, cirrhosis, or renal function groups (all P > .05). Although patients with HBV resistance mutations to LAMþETV group showed better VR compared with the other groups with mutations associated with resistance to ADV (LAMþADV or LAMþADVþETV) (P ¼ .004), there were no differences of VR in each mutation between the TDF-Mono and TDF-Combi groups (all P > .05).
Biochemical and Serologic Responses
Changes in viral load did not differ significantly between the 2 groups. During the follow-up period, the mean serum HBV DNA level in the TDF-Mono and TDF-Combi groups decreased from baseline (-2.4 AE 1.8 vs -2.4 AE 2.0 at 48 weeks and -2.6 AE 2.0 vs -2.2 AE 1.9 log 10 IU/mL at 240 weeks); the differences were not significant ( Table 2) . The mean ALT level was 31.2 IU/L at 48 weeks and 31.7 IU/mL at 240 weeks. During the followup, ALT levels were normalized in 89.6% of patients in the TDF-Mono group, and in 86.3% in the TDF-Combi group.
At 240 weeks, 81 (20.1%) patients experienced HBeAg seroclearance (20.9% in the TDF-Mono group and 20.7% in the TDF-Combi group; P ¼ .340) and 14 (3.6%) showed HBeAg seroconversion (4.9% in the TDF-Mono group and 2.6% in the TDF-Combi group; P ¼ .489). Four patients (1.0%) experienced HBsAg seroclearance (1.2% in the TDF-Mono group and 0.9% in the TDF-Combi group; P ¼ .451) and 6 (1.5%) exhibited HBsAg seroconversion (1.2% in the TDF-Mono group and 1.8% in the TDF-Combi group; P ¼ .872).
Seven patients experienced VBT; 2 in the TDF-Mono group and 5 in the TDF-Combi group. Six patients were men, and 4 had ADV mutation profiles and a high HBV DNA level at baseline (!4.0 log 10 IU/mL). These were transient VBT associated with poor drug adherence; after confirming adherence to antiviral drugs, the virus was well controlled in all patients.
Predictors of Achieving a Virologic Response
We performed univariate and multivariate analyses to identify predictors of VR in patients with MDR (Table 3 ). These analyses included age, gender, the presence of cirrhosis, ALT, HBeAg positivity, baseline HBV DNA level, ADV mutation profiles, and antiviral treatment regimen. Similar to the previous report, 12 we used 4.0 log 10 IU/mL, which was the rounded value of mean HBV DNA level, as the cutoff for distinguishing high and low levels of HBV DNA.
A low HBV DNA level (<4.0 log 10 IU/mL) and the absence of ADV mutation profiles were significant predictors of a VR in the univariate analyses. In the subsequent multivariate analysis, an HBV DNA level <4.0 log 10 IU/mL (hazard ratio, 2.478; 95% confidence interval, 1.959-3.135; P < .001) and the absence of mutations associated with resistance to ADV (hazard ratio, 1.570; 95% confidence interval, 1.279-1.926; P < .001) were significant predictors of a VR. When the cumulative incidence of VR was calculated according to the number of risk factors including HBV DNA level or ADV mutation profiles, the cumulative rates of VR were decreased in the order of no risk factor, ADV mutation only, high viral titer (!4.0 log 10 IU/mL), and both risk factors (P < .001) (Figure 3) . The lower the baseline HBV DNA level (<4.0 log 10 IU/ mL), the higher the likelihood of VR in patients with MDR (P < .001) ( Figure 4A ). In patients with high HBV DNA level (!4.0 log 10 IU/mL), the TDF-Combi group showed a better VR rate in the early phase, but neither difference was statistically significant (P ¼ .051) ( Figure 4B ).
Safety
Most of the enrolled patients tolerated their treatments well. A patient in the TDF-Combi group experienced myositis at 48 weeks (TDF plus telbivudine) and recovered 2 weeks after discontinuation of therapy. Kidney function remained relatively stable during the treatment period in both the TDF-Mono and TDF-Combi groups (Supplementary Figure 2) . Patients with a baseline eGFR <50 mL/min/1.73 m 2 (n ¼ 24) underwent nucleos(t)ide analog dose reduction. There were no events associated with a <30 mL/min/1.73 m 2 decrease in eGFR. Apart from these 24 patients, another 14 experienced increased creatinine from baseline to >1.5 mg/dL. Among them, 11 (78.6%, 11 of 14) had previous ADV exposure. In addition, 8 (57.1%) patients needed dose reduction according to their renal function. The remaining 6 patients naturally recovered to normal renal function without dose reduction.
HCC developed in 8 (1.9%) male patients, 4 of whom had cirrhosis at baseline. Four patients had HBV resistance mutations to LAMþETVþADV, 1 to LAMþADV, and the other to LAMþETV. Although 3 of these 4 patients achieved a VR, their median time to HCC development was 31.7 months.
Discussion
No global consensus has been reached on the efficacy of TDF monotherapy and TDF-based combination therapy in patients with MDR. Although the results of several RCTs have been reported, these do not reflect the realworld situation. Thus, we investigated the efficacy of TDF monotherapy and TDF-based combination therapy in terms of viral suppression in patients with MDR. For long-term treatment of CHB patients with MDR, TDF monotherapy was not inferior to TDF-combination therapy in our large, multicenter, prospective, realworld study.
In patients with antiviral resistance who are difficult to treat, the current guidelines recommend switching to or adding TDF. 10, 17, 18 A generally accepted concept in the management of antiviral resistance is that add-on therapy is more efficacious and safer than switching therapy. In our study, patients with LAMþETVþADV resistance tended to receive combination therapy (n ¼ 24, 9.6%) rather than TDF monotherapy (n ¼ 4, 2.3%). In the TDF-Combi group, the cumulative rates of VR were 68.9% at 48 weeks, 84.2% at 96 weeks, 92.7% at 144 weeks, 95.7% at 192 weeks, and 97.2% at 240 weeks. In the TDF-Mono group, the cumulative rates of VR were 71.7% at 48 weeks, 85.1% at 96 weeks, 92.1% at 144 weeks, 93.4% at 192 weeks, and 97.7% at 240 weeks. There were no significant differences in the long-term cumulative rates of VR between the TDF-Mono and TDF-Combi groups (P ¼ .966). Thus, patients with MDR should be followed-up over a longer period.
Serum HBV DNA level of <4.0 log 10 IU/mL and no ADV-resistance mutation were predictive factors of a VR in patients with MDR. As shown in Figure 3 , viral load among the 2 risk factors was a more powerful factor affecting VR than ADV mutation. TDF monotherapy showed a higher VR rate than TDF combination therapy in patients with a low viral load (HBV DNA <4.0 log 10 IU/mL), but there was no difference between the 2 groups with respect to patients with a high viral load (HBV DNA !4.0 log 10 IU/mL). Another study by Lim et al 12 suggested that combination therapy should be considered in patients with a high baseline HBV DNA level (!4.0 log 10 IU/mL) and LAM and ETV resistance. However, the median follow-up duration was 18 months, which was much shorter than our study. With long-term follow-up, TDF monotherapy showed noninferior VR rates compared with TDF combination therapy even in patients with a high viral load. These results suggest that a high viral load should not be a requirement for TDFcombination therapy in patients with MDR.
Our study has several strengths. First, most previous studies were small RCTs 16, 19 ; by contrast, ours is the first, multicenter, large-scale, real-world cohort study. This study included more than 1000 patients with antiviral resistance, as well as more than 400 patients with MDR. These real-world data will facilitate further research on antiviral resistance. Second, this is the first long-term study (median 4 years, prospectively followed up) conducted in a real-world setting in patients with MDR. Several previous studies reported short-term effects, but few involved long-term follow-up. Third, there are still many MDR patients in Asia. Our results will reduce the economic burden and frequency of side effects of combination therapy in patients with antiviral resistance where cost remains an issue. Fourth, the baseline HBV level was a significant predictor of a treatment response in patients with antiviral resistance, in agreement with previous reports. 12, 20 In patients with high HBV DNA levels, TDF-combination therapy was not superior to TDF monotherapy during the long-term treatment. Therefore, patients with a high viral load can expect to respond to long-term rescue therapy, irrespective of the regimen.
An important question is how long antiviral therapy should be continued. Long-term combination therapy may cause undesirable effects and higher treatment costs, low patient compliance, and safety issues, such as renal function, are matters of concern. In this study, mild adverse events occurred in both the TDF-Mono and TDF-Combi groups, in agreement with previous reports. 21, 22 Our data support the recent concept of switching from combination to monotherapy in patients with antiviral resistance. [23] [24] [25] The cumulative rate of VR at 48 weeks was 71.7% in the TDF-Mono group and 68.9% in the TDF-Combi group. The VR at week 144 was higher than that in another Korean RCT (91.9% vs 74.5%), likely because of use of different definitions of a VR and differences in the study designs. 26 On the other hand, the HBeAg seroconversion rate was lower than previously observed, perhaps because many patients who had already undergone HBeAg loss or seroconversion by previous treatment were included. In addition, it was confirmed that there were no differences in VR regardless of the presence of mutations associated with resistance to ADV ( Supplementary Figure 3) or positivity for HBeAg ( Supplementary Figure 4 ).
There were several limitations of this study. First, the choice of treatment was entirely dependent on the researcher. Thus, combination therapy was applied more frequently in patients with ADV (AELAM or ETV) resistance. In addition, the proportion of cirrhosis at baseline differed slightly between the TDF-Mono and TDF-Combi groups. However, standardization before the analysis removed any difficulty in interpreting the results. Further studies of this cohort with continuous follow-up are planned. Second, because this study was based on real-world practice, dual-energy x-ray absorptiometric assessments could not be performed due to the high cost and difficulty in medical insurance coverage. Therefore, the incidence of osteopenia or osteoporosis, and the change in bone mineral density during the treatment period, was not evaluated. We are planning to evaluate switching to tenofovir alafenamide in these patients with monitoring of bone and renal function.
In conclusion, a virologic response was achieved in the majority of patients with MDR who underwent TDF monotherapy or TDF-based combination therapy during the long-term follow-up. In a multicenter, realworld cohort study, long-term use of TDF monotherapy showed noninferior antiviral efficacy compared with that of TDF-based combination therapy, in patients with MDR. 
